10.6084/m9.figshare.5701258.v1
Zuhua Chen
Zuhua
Chen
Zhentao Liu
Zhentao
Liu
Wenwen Huang
Wenwen
Huang
Zhongwu Li
Zhongwu
Li
Jianling Zou
Jianling
Zou
Jingyuan Wang
Jingyuan
Wang
Xiaoting Lin
Xiaoting
Lin
Beifang Li
Beifang
Li
Dongshao Chen
Dongshao
Chen
Yanting Hu
Yanting
Hu
Jiafu Ji
Jiafu
Ji
Jing Gao
Jing
Gao
Lin Shen
Lin
Shen
MOESM3 of Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
Springer Nature
2017
Gimatecan
Patient-derived xenografts
Gastric cancer
MAPK pathway
2017-12-13 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/MOESM3_of_Gimatecan_exerts_potent_antitumor_activity_against_gastric_cancer_in_vitro_and_in_vivo_via_AKT_and_MAPK_signaling_pathways/5701258
Additional file 3: Figure S3. Gimatecan exerts antitumor activity via AKT and MAPK signaling pathways in HGC27 cells. (A) Gimatecan significantly inhibited the expression of TopI, pAKT, pMEK, and pERK, and activated the expression of p-p38 MAPK and pJUNK2 in HGC27 cells. Cells were starved in serum-free medium overnight, exposed to gimatecan or irinotecan for 48 h and harvested at 70–80% confluence. Total protein of HGC27 was extracted and the expression of TopI, pAKT, pMEK, pERK, p-p38 MAPK and pJNK2 were assessed by western-blotting followed by quantification and normalization by ImageJ. All data are means ± SD of three independent experiments. Compared with controls, *, p < 0.05.